I 

108TH CONGRESS 

1ST SESSION H. R. 2968

To permit biomedical research corporations to engage in certain equity 

financings without incurring limitations on net operating loss 

carryforwards and certain built-in losses, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

JULY 25, 2003

Mr. REYNOLDS (for himself, Mr. CANTOR, Mr. MATSUI, Mr. CARDIN, and Mr. 

HOLT) introduced the following bill; which was referred to the Committee 

on Ways and Means 

A BILL

To permit biomedical research corporations to engage in 

certain equity financings without incurring limitations 

on net operating loss carryforwards and certain builtin losses, and for other purposes.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Biotechnology Future 

5 Investment Expansion Act of 2003’’. 

6 SEC. 2. FINDINGS AND PURPOSE. 

7 (a) FINDINGS.—Congress finds the following: 
2

•HR 2968 IH 

1 (1) American bioscience research corporations 

2 conduct long-term research and development on 

3 breakthrough medical technologies. This commercial 

4 bioscience research industry forms an irreplaceable 

5 link between pure scientific discovery and the devel6 opment of powerful biomedical products and tech7 nologies. It is critical to the maintenance of Amer8 ican competitiveness internationally that these long9 term research and development projects be encour10 aged. 

11 (2) Such long-term research projects have the 

12 greatest potential to revolutionize whole fields of 

13 science and industry for the benefit of the standard 

14 of living of Americans; and to yield solutions for 

15 critical social needs, even though these solutions 

16 might not result in large sales and profits (such as 

17 ‘‘orphan’’ drugs and other treatments alleviating 

18 great suffering in their recipients). 

19 (3) Long-term biomedical research companies 

20 are among the most research-intensive and capital21 intensive companies in the world. 

22 (4) In addition to the scientific and technical 

23 risks attending their long-term research programs, 

24 many biomedical research companies must subject 

25 their technologies to lengthy and expensive regu-
3

•HR 2968 IH 

1 latory reviews before they are permitted access to 

2 the marketplace. 

3 (5) Biomedical research companies typically op4 erate in financially challenging circumstances. These 

5 companies must engage in intensive research activity 

6 for many years in order to develop their products 

7 and earn profits. Many are small businesses lacking 

8 the internal cash flow, stability and borrowing ca9 pacity of large corporations. 

10 (6) The long-term commercial bioscience re11 search industry is heavily dependent on outside 

12 sources of equity capital to fund lengthy and inten13 sive research prior to earning any revenues. The in14 dustry’s long lead times and high levels of scientific 

15 and regulatory risk often impede access to capital. 

16 (7) The longstanding national policy of Govern17 ment support and tax incentives for breakthrough 

18 commercial research reflects a recognition that the 

19 capital marketplace tends to allocate insufficient re20 sources to sustain the Nation’s need for such 

21 foundational scientific research and development. 

22 (8) American long-term bioscience research 

23 companies constitute one of the core commercial sec24 tors which Congress intended to benefit from exist25 ing tax incentives for commercial research. 
4

•HR 2968 IH 

1 (9) However, the current Federal income tax 

2 incentives are simply not working in the case of 

3 many bioscience companies focused on breakthrough 

4 medical technologies. 

5 (10) Current Federal income tax incentives do 

6 not work as intended for most high technology bio7 science companies because they typically incur net 

8 operating losses for a decade or more during their 

9 lengthy research and development phases and there10 fore receive no contemporaneous benefit from these 

11 tax incentives. 

12 (11) Further, Federal tax rules aimed chiefly at 

13 preventing corporate loss trafficking and tax-moti14 vated mergers and acquisitions penalize these com15 panies. The very process of raising successive incre16 ments of private capital through routine equity 

17 financings triggers these rules and subjects bio18 medical research companies to severe limitations on 

19 net operating loss and tax credit carryforwards. 

20 These limitations practically eliminate for the com21 mercial bioscience industry any economic benefit 

22 from these tax incentives. 

23 (12) These tax incentives instead tend to favor 

24 investment by large, profitable companies, often en25 gaged in secondary or tertiary research activities, 
5

•HR 2968 IH 

1 and thus to discriminate against and to cause under2 investment in longer-term breakthrough tech3 nologies, a bias which is harmful to American com4 petitiveness. 

5 (13) The inability to benefit from existing Fed6 eral income tax incentives for commercial research 

7 places long-term bioscience research companies at a 

8 substantial disadvantage in the capital marketplace 

9 where they must compete with other companies able 

10 to use these tax incentives currently. 

11 (14) A tax system that does not discriminate 

12 would ensure that existing tax incentives in favor of 

13 research and experimentation have the same cost-re14 ducing impact on companies conducting both short15 term and long-term research and thus render this 

16 tax incentive program neutral with regard to short17 term and long-term research objectives, minimizing 

18 capital marketplace distortions caused by differences 

19 in tax and income status. 

20 (b) PURPOSE.—The purpose of this Act is to provide 

21 that long-term biomedical research corporations will not 

22 incur limitations on research-related tax incentive 

23 carryforwards simply because they engage in the routine 

24 equity financings that are the financial lifeblood of the in25 dustry. 
6

•HR 2968 IH 

1 SEC. 3. RESTORING THE BENEFIT OF TAX INCENTIVES FOR 

2 BIOMEDICAL RESEARCH AND CLINICAL 

3 TRIALS. 

4 (a) IN GENERAL.—Subsection (l) of section 382 of 

5 the Internal Revenue Code of 1986 is amended by adding 

6 at the end the following new paragraph: 

7 ‘‘(9) CERTAIN FINANCING TRANSACTIONS OF

8 BIOMEDICAL RESEARCH CORPORATIONS.—

9 ‘‘(A) GENERAL RULE.—In the case of a 

10 biomedical research corporation, any owner 

11 shift involving a 5-percent shareholder which 

12 occurs as the result of a qualified investment 

13 during the testing period shall be treated for 

14 purposes of this section (other than this para15 graph) as occurring before the testing period. 

16 ‘‘(B) BIOMEDICAL RESEARCH CORPORA17 TION.—For purposes of this paragraph, the 

18 term ‘biomedical research corporation’ means, 

19 with respect to any qualified investment, any 

20 domestic corporation subject to tax under this 

21 subchapter which is not in bankruptcy and 

22 which, as of the time of the closing on such in23 vestment—

24 ‘‘(i) holds the rights to a drug or bio25 logic for which an investigational new drug 

26 application is in effect under section 505 
7

•HR 2968 IH 

1 of the Federal Food, Drug, and Cosmetic 

2 Act, and 

3 ‘‘(ii) certifies that, as of the time of 

4 such closing, the drug or biologic is under 

5 study in phase II or phase III of a clinical 

6 investigation carried out under such sec7 tion. 

8 ‘‘(C) QUALIFIED INVESTMENT.—For pur9 poses of this paragraph, the term ‘qualified in10 vestment’ means any acquisition of stock in a 

11 biomedical research corporation if such stock is 

12 acquired at its original issue (directly or 

13 through an underwriter), solely in exchange for 

14 cash, and the closing thereon occurs after the 

15 date of the enactment of this paragraph. 

16 ‘‘(D) STOCK ISSUED IN EXCHANGE FOR

17 CONVERTIBLE DEBT.—For purposes of this 

18 paragraph, stock issued by a biomedical re19 search corporation in exchange for its convert20 ible debt (or stock deemed under this section to 

21 be so issued) shall be treated as stock acquired 

22 by the debt holder at its original issue and sole23 ly in exchange for cash if the debt holder pre24 viously acquired the convertible debt at its 

25 original issue and solely in exchange for cash. 
8

•HR 2968 IH 

1 In the case of an acquisition of stock in ex2 change for convertible debt, the requirements of 

3 this paragraph shall be applied separately as of 

4 the time of closing on the investment in con5 vertible debt, and as of the time of actual con6 version (or deemed conversion under this sec7 tion) of the convertible debt for stock, except 

8 that the requirements of subparagraph (H) 

9 shall be applied only as of the time of closing 

10 on the issuance of the convertible debt. 

11 ‘‘(E) BIOMEDICAL RESEARCH CORPORA12 TION MUST MEET 5-YEAR EXPENDITURE TEST

13 WITH RESPECT TO ANY QUALIFIED INVEST14 MENT.—

15 ‘‘(i) IN GENERAL.—This paragraph 

16 shall not apply to a qualified investment in 

17 a biomedical research corporation unless 

18 such corporation meets the expenditure 

19 test for each year of the measuring period. 

20 ‘‘(ii) MEASURING PERIOD.—For pur21 poses of this subparagraph, the term 

22 ‘measuring period’ means, with respect to 

23 any qualified investment, the taxable year 

24 of the biomedical research corporation in 

25 which the closing on the investment occurs, 
9

•HR 2968 IH 

1 the 2 preceding taxable years, and the 2 

2 subsequent taxable years. 

3 ‘‘(iii) EXPENDITURE TEST.—A bio4 medical research corporation meets the ex5 penditure test of this subparagraph for a 

6 taxable year if at least 25 percent of its ex7 penditures for the taxable year (including, 

8 for purposes of this clause, payments in re9 demption of its stock) are expenditures de10 scribed in section 41(b) which are paid or 

11 incurred for clinical testing or preclinical 

12 biomedical research. 

13 ‘‘(iv) CLINICAL TESTING.—For pur14 poses of this subparagraph, the term ‘clin15 ical testing’ means any human clinical test16 ing which is carried out under any inves17 tigational new drug application in effect 

18 under section 505 of the Federal Food, 

19 Drug, and Cosmetic Act. 

20 ‘‘(F) EFFECT OF CORPORATE REDEMP21 TIONS ON QUALIFIED INVESTMENTS.—Rules 

22 similar to the rules of section 1202(c)(3) shall 

23 apply to qualified investments under this para24 graph except that ‘stock acquired in a qualified 

25 investment’ shall be substituted for ‘qualified 
10

•HR 2968 IH 

1 small business stock’ each place it appears 

2 therein. 

3 ‘‘(G) EFFECT OF OTHER TRANSACTIONS

4 BETWEEN BIOMEDICAL RESEARCH CORPORA5 TIONS AND INVESTORS MAKING QUALIFIED IN6 VESTMENTS.—

7 ‘‘(i) IN GENERAL.—If, during the 2-

8 year period beginning 1 year before any 

9 qualified investment, the biomedical re10 search corporation engages in another 

11 transaction with a member of its qualified 

12 investment group and such biomedical re13 search corporation receives any consider14 ation other than cash in such transaction, 

15 there shall be a presumption that stock re16 ceived in the otherwise qualified investment 

17 transaction was not received solely in ex18 change for cash. 

19 ‘‘(ii) QUALIFIED INVESTMENT

20 GROUP.—For purposes of this subpara21 graph, the term ‘qualified investment 

22 group’ means, with respect to any qualified 

23 investment, one or more persons who re24 ceive stock issued in exchange for the 

25 qualified investment, and any person re-
11

•HR 2968 IH 

1 lated to such persons within the meaning 

2 of section 267(b) or section 707(b). 

3 ‘‘(iii) REGULATIONS.—The Secretary 

4 shall promulgate regulations exempting 

5 from this subparagraph transactions which 

6 are customary in the bioscience research 

7 industry and are of minor value relative to 

8 the amount of the qualified investment. 

9 ‘‘(H) PROCEEDS OF QUALIFIED INVEST10 MENTS SHALL BE DEVOTED TO RESEARCH ON

11 PREEXISTING TECHNOLOGY.—

12 ‘‘(i) IN GENERAL.—This paragraph 

13 shall not apply to any qualified investment 

14 unless the net proceeds of such qualified 

15 investment do not exceed the excess of—

16 ‘‘(I) the sum of the biomedical 

17 research corporation’s aggregate 

18 qualifying clinical expenditures for the 

19 3 years following the qualified invest20 ment, over 

21 ‘‘(II) three times the corpora22 tion’s qualifying clinical expenditures 

23 for the year preceding the qualified 

24 investment, plus the amount of the 

25 corporation’s cash and cash equiva-
12

•HR 2968 IH 

1 lents immediately before the closing 

2 on the qualified investment. 

3 ‘‘(ii) QUALIFYING CLINICAL EXPENDI4 TURES.—For purposes of this subpara5 graph, the term ‘qualifying clinical expend6 itures’ means amounts described in section 

7 41(b) which are paid or incurred by a bio8 medical research corporation for clinical 

9 testing in connection with a drug or bio10 logic for which an investigational new drug 

11 application is in effect under section 505 

12 of the Federal Food, Drug, and Cosmetic 

13 Act and which is (at the time of the clos14 ing on the qualified investment) under 

15 study in phase II or phase III of a clinical 

16 investigation carried out under such sec17 tion. 

18 ‘‘(I) REGULATIONS.—The Secretary may 

19 issue such regulations as may be appropriate to 

20 achieve the purposes of this paragraph, to pre21 vent abuse, and to provide for treatment of bio22 medical research corporations under sections 

23 383 and 384 that is consistent with the pur24 poses of this paragraph.’’. 
13

•HR 2968 IH 

1 (b) PROCEEDS OF EQUITY INVESTMENTS TO BE

2 TREATED AS WORKING CAPITAL.—Subparagraph (C) of 

3 section 382(l)(4) of such Code is amended by adding at 

4 the end the following: ‘‘Such term shall not include any 

5 assets reasonably expected to be used within 3 years to 

6 fund qualifying clinical expenditures (as defined in para7 graph (9)(H)(ii) without regard to the parenthetical there8 in).’’. 

9 (c) EFFECTIVE DATE.—The amendments made by 

10 this section shall apply to taxable years beginning after 

11 December 31, 2002.

Æ